153 related articles for article (PubMed ID: 12882616)
1. Promising candidates for the treatment of chronic hepatitis C.
Walker MP; Yao N; Hong Z
Expert Opin Investig Drugs; 2003 Aug; 12(8):1269-80. PubMed ID: 12882616
[TBL] [Abstract][Full Text] [Related]
2. Future directions in therapy for chronic hepatitis C.
Jensen DM; Ascione A
Antivir Ther; 2008; 13 Suppl 1():31-6. PubMed ID: 18432161
[TBL] [Abstract][Full Text] [Related]
3. New targets for antiviral therapy of chronic hepatitis C.
Bühler S; Bartenschlager R
Liver Int; 2012 Feb; 32 Suppl 1():9-16. PubMed ID: 22212566
[TBL] [Abstract][Full Text] [Related]
4. Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues.
Brown NA
Expert Opin Investig Drugs; 2009 Jun; 18(6):709-25. PubMed ID: 19426125
[TBL] [Abstract][Full Text] [Related]
5. Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection.
Chen SH; Tan SL
Curr Med Chem; 2005; 12(20):2317-42. PubMed ID: 16181135
[TBL] [Abstract][Full Text] [Related]
6. Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.
Sultanik P; Mallet V; Lagaye S; Casrouge A; Dorival C; Barthe Y; Fontaine H; Hézode C; Mottez E; Bronowicki JP; Carrat F; Theodorou I; Abel L; Gayat E; Fontanet A; Pol S; Albert ML;
Liver Int; 2015 Jul; 35(7):1833-44. PubMed ID: 25556540
[TBL] [Abstract][Full Text] [Related]
7. TMC-435, an NS3/4A protease inhibitor for the treatment of HCV infection.
Tsantrizos YS
Curr Opin Investig Drugs; 2009 Aug; 10(8):871-81. PubMed ID: 19649931
[TBL] [Abstract][Full Text] [Related]
8. Nucleoside analog inhibitors of hepatitis C viral replication: recent advances, challenges and trends.
Furman PA; Lam AM; Murakami E
Future Med Chem; 2009 Nov; 1(8):1429-52. PubMed ID: 21426058
[TBL] [Abstract][Full Text] [Related]
9. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibitors of hepatitis C virus replication.
Neyts J
Antiviral Res; 2006 Sep; 71(2-3):363-71. PubMed ID: 16843538
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus therapies: current treatments, targets and future perspectives.
Walker MP; Appleby TC; Zhong W; Lau JY; Hong Z
Antivir Chem Chemother; 2003 Jan; 14(1):1-21. PubMed ID: 12790512
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus resistance to protease inhibitors.
Halfon P; Locarnini S
J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
[TBL] [Abstract][Full Text] [Related]
13. [New possibilities on the horizon for the treatment of hepatitis C virus infection: direct-acting antiviral therapy].
Pár A
Orv Hetil; 2010 Dec; 151(50):2045-56. PubMed ID: 21126947
[TBL] [Abstract][Full Text] [Related]
14. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells.
Lin K; Kwong AD; Lin C
Antimicrob Agents Chemother; 2004 Dec; 48(12):4784-92. PubMed ID: 15561857
[TBL] [Abstract][Full Text] [Related]
15. A review of HCV protease inhibitors.
Chen KX; Njoroge FG
Curr Opin Investig Drugs; 2009 Aug; 10(8):821-37. PubMed ID: 19649927
[TBL] [Abstract][Full Text] [Related]
16. [Telaprevir resistance].
Poveda E; García F
Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():26-32. PubMed ID: 24063900
[TBL] [Abstract][Full Text] [Related]
17. New antiviral therapies in the management of HCV infection.
Farnik H; Zeuzem S
Antivir Ther; 2012; 17(5):771-83. PubMed ID: 22626842
[TBL] [Abstract][Full Text] [Related]
18. New NS5B polymerase inhibitors for hepatitis C.
Legrand-Abravanel F; Nicot F; Izopet J
Expert Opin Investig Drugs; 2010 Aug; 19(8):963-75. PubMed ID: 20629614
[TBL] [Abstract][Full Text] [Related]
19. HCV NS5B polymerase inhibitors.
Burton JR; Everson GT
Clin Liver Dis; 2009 Aug; 13(3):453-65. PubMed ID: 19628161
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C: therapeutic perspectives.
Cornberg M; Wedemeyer H; Manns MP
Forum (Genova); 2001; 11(2):154-62. PubMed ID: 11948360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
